Clinical Trial Detail

NCT ID NCT03634228
Title Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

Therapies

Cytarabine + Milademetan Tosylate

Cytarabine + Milademetan Tosylate + Venetoclax

Age Groups: senior adult

No variant requirements are available.